RPT-The cost of cancer: new drugs show success at a steep price

RPT-The cost of cancer: new drugs show success at a steep price


Newer cancer drugs that enlist the body's immune system are improving the odds of survival, but competition between them is not reining in prices that can now top $250,000 a year. The drugs' success for patients is the result of big bets in cancer therapy made by Bristol-Myers Squibb Co, Merck & Co Inc and Roche Holding AG, among others in big pharma.



from Biotech News